The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2022 | Unmet needs and future questions in cellular therapy for myeloma
Adam Cohen
• 26 Aug 2022
Adam Cohen, MD, University of Pennsylvania, Philadelphia, PA, highlights key unmet needs in cellular therapy for multiple myeloma, including the need to improve manufacturing processes and patient responses, as well as better mitigate toxicities associated with CAR-T products. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
